Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Histopathological characteristics of breast cancers in individuals with TP53 germline mutations

From: Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients

Mutation Patient no. Age at diagnosis Diagnosis Histology Grade ER status PR status HER-2 status
p. E346X BRC 901 25 Breast ca, L IDC with DCIS NA - + +
   26 Breast ca, L IDC 3 + + 3+
   29 Breast ca, R IDC NA NA NA NA
p. G334_R335dup BRC 564 26 Breast ca, R IDC NA NA NA NA
   27 Breast ca, L IDC 3 - + 3+
p. A138V BRC 349 33 Breast ca, R IDC 3 - - 3+
  BRC 349A 33 Breast ca, L IDC 2 - - -
p. E285K BRC 832 31 Breast ca, R IDC 2 - - 3+
  BRC 873 29 Breast ca, R IDC with DCIS 3 - - 3+
   31 Breast ca, L NA NA NA NA NA
  BRC 873A 27 Breast ca, L NA NA NA NA NA
   31 Breast ca, R Mucinous 2 + + 3+
  1. Breast ca, breast cancer; DCIS, ductal carcinoma in situ; ER, estrogen receptor; IDC, invasive ductal carcinoma; HER-2, human epidermal growth factor receptor 2; L, left; NA, not available; PR, progesterone receptor; R, right